OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC

February 2nd 2024

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

February 2nd 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

February 2nd 2024

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in PDAC

February 2nd 2024

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.

Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC

February 2nd 2024

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNs

February 2nd 2024

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Dr Sharma on Questions Regarding the Optimal Use of Triplet Therapies in HSPC

February 2nd 2024

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer

February 2nd 2024

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast Cancer

February 1st 2024

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCC

February 1st 2024

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

February 1st 2024

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Dr Garmezy on the Impact of Combination Regimens on Outcomes and Quality of Life in Patients With RCC

February 1st 2024

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

February 1st 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

January 31st 2024

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.

Dr Hashmi on Real-World Teclistamab Use in Relapsed/Refractory Multiple Myeloma

January 31st 2024

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer

January 31st 2024

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Dr Battiwalla on Outpatient CAR T-Cell Therapy Administration in Hematologic Malignancies

January 31st 2024

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPC

January 31st 2024

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.